Drug Database
Back to search

Poland· PL-100080823

Gabitril

A tiagabine product containing tiagabinum, registered in Poland by Teva Pharmaceuticals Polska Sp. z o.o.. The same ATC class is registered in 9 of our 19 countries.

ATC N03AG06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedGabitrilATCN03AG06REGISTER NO.PL-100080823PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tiagabinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tiagabine is registered in 9 of 19 countries.

Countries holding a registration under ATC N03AG06 (tiagabine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search tiagabine products by name

Tiagabine · ATC N03AG06

9 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Franceprice
  • Ireland
  • Italyprice
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tiagabine costs, country by country.

Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Tiagabine · price per daily dose (30 mg)

USD · FX 28 Sept 2026

  • IT Italy$3.98
  • FR France$3.35
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Tiagabinum
Manufacturer
Teva Pharmaceuticals Polska Sp. z o.o.
Country
Poland (PL)
ATC code
N03AG06
ATC class
Tiagabine
Defined daily dose
30 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

1 priced
  • gtin
    05909990058822
    50 szt.
    PLN 96.17
  • gtin
    05909990764419
  • gtin
    05909990764426

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

163 interactions on record for tiagabine.

Graded by severity as the source publishes them — 92 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tiagabine against other medicinesHow interaction checks work

Tiagabine · interactions on record

163 records

  • 92 moderate
  • 46 info

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • DiphenhydraminA04AB05moderate
  • DronabinolA04AD10moderate
  • NabiloneA04AD11moderate

25 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tiagabine in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tiagabine products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Belgium · Gabitril
  • Spain · Gabitril
  • France · Gabitril
  • United Kingdom (Northern Ireland) · Gabitril
  • Ireland · Gabitril
  • Italy · Gabitril
  • Luxembourg · Gabitril
  • Portugal · Gabitril

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/701ff083-9e08-4af0-9784-917bf1c8e212
GET /v1/drugs/701ff083-9e08-4af0-9784-917bf1c8e212?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "05909990764419 ¦ Rp ¦ Skasowane ¦ 12162\n50 tabl.\n05909990764426 ¦ Rp ¦ Skasowane ¦ 12163\n100 tabl.\n05909990058822 ¦ Rp ¦ 16690\n50 tabl.",
  "substance": "Tiagabinum 5 mg",
  "common_name": "Tiagabinum",
  "pl_product_id": "100080823",
  "pozwolenie_nr": "07644",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about tiagabine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console